Oral Immunotherapy with a Phosphorylated Hypoallergenic Allergen Ameliorates Allergic Responses More Effectively Than Intact Allergen in a Murine Model of Buckwheat Allergy,Molecular Nutrition & Food Research

当前位置： X-MOL 学术 › Mol. Nutr. Food Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Oral Immunotherapy with a Phosphorylated Hypoallergenic Allergen Ameliorates Allergic Responses More Effectively Than Intact Allergen in a Murine Model of Buckwheat Allergy
Molecular Nutrition & Food Research ( IF 4.5 ) Pub Date : 2018-09-14 , DOI: 10.1002/mnfr.201800303
Shigeru Katayama _{1,

2} , Daiki Yamaguchi ₁ , Yuta Suzuki ₁ , Ahmad M. Al Athamneh _{1,

3} , Takakazu Mitani _{1,

2} , Rie Satoh ₄ , Reiko Teshima ₅ , Yoshinori Mine ₆ , Soichiro Nakamura ₁

Affiliation

Buckwheat is a common food allergen frequently consumed in Asian countries, with Fag e 1 and Fag e 2 being the major buckwheat allergens. The purpose of this study is to prepare an oral immunotherapy agent by attenuating these allergens via phosphorylation. The immunomodulatory effects of phosphorylated Fag e 2 (P‐Fag e 2) in a mouse model of buckwheat allergy are evaluated.

中文翻译：

磷酸化低变应原变应原的口服免疫疗法比荞麦变态反应小鼠模型中的完整变应原更有效地改善了变态反应。

荞麦是亚洲国家经常食用的常见食物过敏原，其中Fag e 1和Fag e 2是主要的荞麦过敏原。这项研究的目的是通过磷酸化减弱这些过敏原来制备口服免疫治疗剂。评估了荞麦变态反应小鼠模型中磷酸化Fag e 2（P-Fag e 2）的免疫调节作用。

更新日期：2018-09-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11